Physician profile
Archi Patel
NPI 1891394714
$9,279.71
in general payments reported to CMS, 2019-2025
32 companies · $890 in 2025
The $890 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,340 · 2022: $2,472 · 2023: $2,842 · 2024: $1,735 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,358 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.89 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,139.84 | 2021-2025 | Caplyta |
| Alkermes, INC. | $974.12 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $895.59 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $812.17 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $774.39 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $697.78 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $571.97 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $452.48 | 2022-2025 | Ingrezza |
| Bausch Health US, LLC | $363.48 | 2022-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $346.15 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $319.37 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $202.59 | 2022-2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $181.85 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $145.70 | 2022-2023 | Adzenys Xr-Odt |
| Eisai INC. | $140.17 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.54 | 2022-2023 | Belsomra |
| Corium, LLC | $132.64 | 2022-2024 | Azstarys |
| Novo Nordisk INC | $115.54 | 2023-2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $114.36 | 2021 | |
| Indivior INC. | $99.20 | 2022 | |
| Noven Therapeutics, LLC | $79.60 | 2022 | |
| Sage Therapeutics, LLC | $78.85 | 2022-2024 | |
| Biogen, INC. | $70.88 | 2022-2025 | Leqembi |
| E.R. Squibb & Sons, L.L.C. | $65.89 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $62.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $59.41 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $59.21 | 2021-2023 | Qelbree |
| Acadia Pharmaceuticals INC | $53.70 | 2022-2024 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $46.62 | 2022 | |
| Jazz Pharmaceuticals INC. | $39.49 | 2022-2023 | |
| Owp Pharmaceuticals, INC. | $32.31 | 2021 | |
| Bioxcel Therapeutics, INC. | $16.76 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.